Complete biosynthesis of opioids in yeast

Area of Science:

• Biotechnology
• Synthetic Biology
• Biochemistry

Background:

• Opioids are crucial for pain management and palliative care in Western medicine.
• Current opioid supply relies solely on opium poppy farming, facing challenges from climate change and pests.
• Ensuring a stable and sustainable supply of essential opioids is a significant concern.

Purpose of the Study:

• To engineer yeast for the biosynthesis of opioid compounds, specifically thebaine and hydrocodone.
• To establish a proof-of-principle for producing medically relevant opioids from a non-plant source.
• To explore alternative biotechnological routes for opioid production.

Main Methods:

• Utilized enzyme discovery and engineering to identify and optimize necessary catalytic activities.
• Designed and implemented complex metabolic pathways for full opiate biosynthesis in yeast.
• Integrated enzymes from diverse organisms (plants, mammals, bacteria, yeast) into engineered strains.

Main Results:

• Successfully engineered yeast strains capable of producing thebaine and hydrocodone from simple sugars.
• Achieved full opioid biosynthesis pathways requiring expression of 21 (thebaine) and 23 (hydrocodone) enzyme activities.
• Demonstrated the feasibility of producing opioids through a synthetic biology approach.

Conclusions:

• Yeast can be engineered to produce key opioid compounds, offering a potential alternative to traditional agriculture.
• Significant challenges remain in optimizing and scaling this technology for commercial viability.
• Responsible governance and open discussion are necessary for the ethical implementation of this biotechnological advancement.